Immix Biopharma (IMMX) said Tuesday that updated data for its drug NXC-201 showed a 94% overall response rate in patients with AL amyloidosis.
The drug had a complete response rate of 75% in the phase 1b/2 Nexicart-1 study, according to the company.
One patient maintained a complete response for 31.5 months, with ongoing remission as of Dec. 9, Immix added.
Shares of Immix were down 7.4% in recent trading.
Price: 2.25, Change: -0.29, Percent Change: -11.42
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。